Pete Frates’ family launches Ice Bucket Challenge 2.0 for ALS
A decade later, the family of Pete Frates, the amyotrophic lateral sclerosis (ALS) patient who helped start the…
Articles by Margarida Maia, PhD
TPN-101 shows long-term benefits in C9orf72-related ALS in trial
Nearly a year of treatment with TPN-101, an investigational oral molecule from Transposon Therapeutics, safely slowed disease progression and…
Early PrimeC initiation slows lung function decline, trial data show
People with amyotrophic lateral sclerosis (ALS) who received one year of treatment with PrimeC, an experimental oral tablet from…
Blood NfL levels are impacted by ALS clinical subtype, study finds
Elevated blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, are linked to faster disease progression…
Europe’s CHMP recommends against masitinib authorization
An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as…
Fasudil safe, preserves motor neurons in early-stage ALS: Study
Treatment with fasudil (RT1968), which Raya Therapeutic is testing for amyotrophic lateral sclerosis (ALS), was safe and outperformed…
AB Science expects negative opinion on masitinib application in Europe
An advisory committee of the European Medicines Agency (EMA) is leaning against recommending the conditional approval of AB Science’s…
Clene expanding CNM-Au8 expanded access program in US
Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients…
Patient guide aims to increase, diversify clinical trial participation
The Les Turner ALS Foundation, in an effort to boost and diversify clinical trial participation, has written a step-by-step…
Extended treatment with NurOwn may offer additional benefits in ALS
People with amyotrophic lateral sclerosis (ALS) who continued treatment with NurOwn (debamestrocel) after completing a Phase 3 trial…